Funding for this research was provided by:
Ligue Contre le Cancer (EL2016, EL2019)
Association La Marie-Do
Centre d’Investigations Cliniques (CICp1409)
Received: 27 August 2020
Accepted: 27 April 2021
First Online: 18 May 2021
: The PERMED-01 trial was approved by the French National Agency for Medicines and Health Products Safety ANSM; ref 140823B-12, a national ethics committee (CPP Sud-Méditerranée I; ref 1456), and our Institut Paoli-Calmettes Institutional Review Board (reference number: 2014-003). All patients gave their informed consent for inclusion, biopsy, and genomic analysis and to participate in the study. The research was conducted in strict compliance with the Helsinki Declaration.
: Not applicable.
: The authors declare that they have no competing interests.